Are There Peptide Protocols for Perimenopausal Women?

Perimenopause does not begin when your periods stop. It begins years earlier, and the first thing to change is not estrogen.

Progesterone drops first. The reason is mechanical. Every month when your ovaries release an egg, the follicle left behind transforms into something called the corpus luteum, which is a temporary gland that produces progesterone for the second half of your cycle. When ovulation starts becoming inconsistent, which is what happens in your late thirties and early forties, you lose that source. Less ovulation means less corpus luteum means less progesterone. And that decline happens well before estrogen starts changing in any meaningful way.

What happens to estrogen is the part most people get wrong.

The common belief is that perimenopause is a state of low estrogen, and that belief is understandable because that is how menopause is described. But Santoro and colleagues documented in 2004 that estrogen in perimenopause does not simply decline. It becomes erratic. It spikes higher than it ever did during your reproductive years, then crashes, then spikes again. The pattern is unstable in both directions.

So what you actually have in perimenopause is low progesterone alongside wildly fluctuating estrogen. The ratio between the two breaks down. And it is that broken ratio, not simply low estrogen, that drives the symptom cluster most women are experiencing: disrupted sleep, anxiety, visceral fat accumulating around the midsection, and changes in body composition that happen even when training and nutrition have not changed.

That context matters enormously before you talk about any intervention, hormonal or otherwise.

The appropriate first step, as Prior outlined in 2014, is progesterone replacement, not estrogen. Adding estrogen when your ovaries are still producing it unpredictably can amplify the erratic pattern rather than smooth it out. Oral micronized progesterone specifically has the evidence behind it. A Phase III randomized controlled trial published in 2023 by Prior and colleagues showed that oral micronized progesterone improved sleep quality and reduced night sweats compared to placebo, which maps directly onto the symptom profile caused by the progesterone withdrawal.

The question of when to add estrogen has a fairly clear marker. Your doctor can measure something called anti-Mullerian hormone, which is a signal produced by the small follicles in your ovaries and functions as a read on how much ovarian reserve you have remaining. The Penn Ovarian Aging Study, which followed 401 women over 14 years, found that AMH levels predicted menopause timing with meaningful accuracy. When AMH is essentially undetectable and you have gone 12 consecutive months without a period, ovarian function has ended and you are in menopause. That is the point at which estrogen replacement becomes appropriate and stable.

Now, within that hormonal framework, there are peptides that can be useful. But the word useful needs to be defined precisely here.

Peptides in this context are managing specific downstream symptoms. They are not correcting the hormonal imbalance driving those symptoms. That distinction matters because a woman who layers peptides on top of an unaddressed progesterone deficiency is solving for surface problems while leaving the root cause intact.

With that framing, there are three areas where peptides have a rational role.

The first is metabolic. The erratic estrogen and progesterone imbalance of perimenopause promotes visceral fat accumulation and increases food-seeking behavior, which makes energy balance harder to manage even when nothing external has changed. GLP-1 receptor agonists like tirzepatide, and the newer GLP-1/GIP/glucagon triple agonist retatrutide, work on the satiety signaling in the brain to reduce what is often called food noise, which is the persistent background drive to eat that undermines intake control. Getting body composition moving in the right direction reduces the metabolic burden of perimenopause significantly.

The second area is sleep and anxiety. Selank is a synthetic analog of a naturally occurring peptide called tuftsin, and it works on the GABAergic system, which is the brain's primary inhibitory signaling pathway, the same system benzodiazepines act on, though through a different and more targeted mechanism. DSIP, or delta sleep inducing peptide, acts on sleep architecture more directly. Both can help manage the anxiety and sleep disruption that low progesterone produces, though the evidence base here is thinner than for the GLP-1 class and the mechanisms are largely characterized in animal and early human work.

The third area is the growth hormone axis. As body composition shifts and muscle maintenance becomes harder, some clinicians add a growth hormone secretagogue like tesamorelin or CJC-1295, which work by stimulating the pituitary to produce more growth hormone, which then drives IGF-1 production and the downstream tissue repair and body composition effects associated with it.

This is where the estrogen dependency becomes important.

Shah and colleagues published data in 2019 in the Journal of Clinical Endocrinology and Metabolism showing that pulsatile growth hormone secretion was significantly blunted in women without adequate estradiol, with a p-value of 0.001. The mechanism is that estrogen potentiates the pituitary's response to growth hormone releasing hormone. Without it, the pituitary is less sensitive to the secretagogue signal. Which means if you are using a growth hormone peptide while estrogen is still erratic and deficient, you are running that intervention at a fraction of its potential effect.

The practical sequence that follows from all of this is fairly direct. Address the progesterone deficiency first. Monitor AMH to know where you are in the transition. Add estrogen when ovarian function has actually ended. Then build the peptide layer on top of a stabilized hormonal foundation, targeting metabolism, sleep, and the growth hormone axis in that order of evidence strength.

The reason this ordering matters is that hormones set the sensitivity of the systems that peptides act on. You are not fighting the foundation when you get this in sequence. You are working with it.

---

References

1. Santoro et al., 2004, Journal of Clinical Endocrinology & Metabolism — progesterone declines before estrogen, estrogen becomes erratic during perimenopause
2. Freeman et al., 2012, Journal of Clinical Endocrinology & Metabolism — AMH predicts menopause timing (Penn Ovarian Aging Study, 401 women, 14 years)
3. Prior, 2014, Facts, Views & Vision in ObGyn — progesterone as appropriate first-line therapy for perimenopause
4. Shah et al., 2019, Journal of Clinical Endocrinology & Metabolism — pulsatile GH secretion significantly blunted without estradiol (P = 0.001), estrogen potentiates pituitary GHRH response
5. Prior et al., 2023, Scientific Reports — Phase III RCT, oral micronized progesterone improved sleep quality and reduced night sweats vs placebo

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness